This article discusses a study conducted in Greece on children with severe hemophilia A who were exclusively treated with recombinant factor VIII (FVIII) concentrates. The aim of the study was to identify genetic factors that may influence the development of FVIII inhibitors in these patients. The study found that certain genetic pathogenic variants, such as inversion-22 (Inv-22) and large deletions, were associated with a higher risk of inhibitor development. Additionally, specific HLA alleles, such as DRB1*01:01 and DQB1*05:01, were also found to be associated with inhibitor development. The authors suggest that this knowledge could contribute to the therapeutic management of the disease. [Extracted from the article]